Discovery of Potent DYRK2 Inhibitors with High Selectivity, Great Solubility, and Excellent Safety Properties for the Treatment of Prostate Cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.3c00106
Abstract: Prostate cancer (PCa) is a common male cancer with high incidence and mortality, and hormonal therapy as the major treatment for PCa patients is troubled by the inevitable resistance that makes us identify novel targets… read more here.
Keywords: prostate cancer; safety properties; potent dyrk2; high selectivity ... See more keywords
Discovery of the First Potent DYRK2 Proteolysis Targeting Chimera Degraders.
Sign Up to like & getrecommendations! Published in 2024 at "ACS medicinal chemistry letters"
DOI: 10.1021/acsmedchemlett.4c00065
Abstract: Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) has been identified as a promising oncogenic driver of several types of cancer and is considered to be a critical cancer therapeutic target. Several inhibitors of DYRK2 have been… read more here.
Keywords: discovery first; first potent; potent dyrk2; dyrk2 ... See more keywords